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1. Introduction 
This chapter will provide a comprehensive review of post-infectious glomerulonephritis 
focusing in particular on the changing epidemiology and long term outcome. 
The immunological response of the kidney to an insult results in glomerulonephritis. The 
insult can result from a large number of conditions, both infectious and non-infectious. 
Regardless of the initial insult, the outcome is similar in terms of pathology and clinical 
symptoms. The most common and most-studied cause is post streptococcal 
Glomerulonephritis (PSGN). A list of causes is presented in Table 1.  
 
INFECTIOUS 
Bacterial: Streptococcal (PSGN), methicillin-resistant Staphylococcus aureus (MRSA), 
pneumococcal pneumonia, typhoid, secondary syphilis, meningococcemia, infective 
endocarditis, shunt nephritis, sepsis 
Viral: Hepatitis B, infectious mononucleosis, mumps, measles, varicella, vaccinia, 
echovirus, parvovirus, and coxsackievirus 
Parasitic: Malaria, toxoplasmosis
Fungal: cryptococccus imitis
 
NON INFECTIOUS
Primary glomerular diseases: Membranoproliferative GN (MPGN), IgA nephropathy, 
mesangial proliferative GN 
Multisystem systemic diseases: Systemic lupus erythematosus, vasculitis, Henoch-Schönlein 
purpura, Goodpasture syndrome, Wegener granulomatosis  
Miscellaneous: Gullian-barre syndrome, pertussis-tetanus vaccine, serum sickness 
Table 1. Causes of post-Infectious Glomerulonephritis 
2. Burden of disease and changing epidemiology 
Of all the bacterial pathogens, group A streptococcus (GAS) causes the widest range of 
illness in humans. These illnesses range from local infections of the skin and throat 
(impetigo and pharyngitis respectively) to invasive infections as well as the significant post-
infectious immunological sequelae such as the well documented acute rheumatic fever and 
acute post-streptococcal glomerulonephritis and the lesser known PANDAS (Paediatric 
Autoimmune Neuropsychiatric Disorder Associated with Streptococcus) [1]. 
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While global estimates of the burden of disease due to GAS infections are difficult to get, 
some estimates have been reported which are based on published population studies. The 
estimate of 500 000 deaths per year due to GAS makes it a major human Pathogen [2]. This 
minimal estimate places GAS infections as less common than HIV, Mycobacterium 
tuberculosis, Plasmodium falciparum and Streptococcus pneumonia but as common as rotavirus, 
measles, Haemophilus influenzae type b and hepatitis B as a cause of global mortality [2]. In 
addition there is the long-term morbidity associated with GAS infections.  
The global burden of severe group A streptococcal disease is concentrated largely in 
developing countries and within disadvantaged populations living in developed countries 
such as Aboriginal Australians. The review of population based studies estimated the 
prevalence of severe GAS disease at a minimum of 18·1 million cases, with 1·78 million new 
cases each year [2]. The greatest burden was due to rheumatic heart disease, with a 
prevalence of at least 15·6 million cases, with 282 000 new cases and 233 000 deaths each 
year. The burden of invasive GAS diseases was found to be unexpectedly high, with at least 
663 000 new cases and 163 000 deaths each year. In addition, there were more than 111 
million prevalent cases of GAS pyoderma, and over 616 million incident cases per year of 
GAS pharyngitis [2]. The review estimated that over 470 000 cases of acute post-
streptococcal glomerulonephritis occur annually, with approximately 5000 deaths (1% of 
total cases), 97% of which were in less developed countries [2]. 
The global incidence of acute PSGN was estimated at 472,000 cases per year, of which 
456,000 ( 96.6%) occurred in less developed countries [3, 4]. A similar distribution of higher 
incident cases in less developed countries is also reported in a review of population based 
studies [2]. A review of 11 population-based studies documenting the incidence of acute 
PSGN in children from less developed countries or those that included substantial minority 
populations in more developed countries, estimated 24·3 cases per 100,000 person as the 
median PSGN incident rate [2]. The same review estimated an incidence in adults of 2 cases 
per 100,000 person-years for developing countries and 0.3 per 100,000 person-years in 
developed countries [2]. Due to the paucity of data in adults with PSGN, the estimate for 
developing countries was based on data from Kuwait and for developed countries on data 
from Italian Biopsy Registry and the most conservative estimates were reported [2]. Another 
recent study described a slightly higher incidence of 9.5-28.5 cases per 100,000 person-years 
in developing countries [5]. These rates represent only the clinical cases. When 
asymptomatic cases are screened for in household contacts and family members, 
asymptomatic disease is reported to be 4-19 times greater [5-7].  
PSGN can occur sporadically or epidemically. The changing pattern of PSGN over the last 
few decades has been described in studies from Florida [8] and Singapore [9]. The overall 
incidence of PSGN has decreased over the last few decades [10]. The reasons for this 
decline have not been clearly delineated but possible reasons are the widespread use of 
antibiotics, changes in etiological pathogens, altered susceptibility of the host, better 
health care delivery and improved socioeconomic and nutritional conditions [8-10]. 
Nevertheless, epidemics and clusters of cases continue to appear in several regions of the 
world and sporadic cases of PSGN account for 21% (4.6–51.6%) of children admitted to the 
hospital with acute renal failure in developing countries [5]. Although epidemic PSGN 
has decreased dramatically and is almost unknown in the developed world, epidemics of 
PSGN continue to occur in the developing world, mainly in Africa, West Indies and the 
Middle East, as well as in Indigenous people living in the developed world [11]. 
Epidemics are described mainly in “closed” communities, clusters of densely populated 
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dwellings or areas with poor hygienic conditions, both urban and rural. These conditions 
are especially prevalent in Aboriginal peoples of Australia living in remote communities, 
in settings with a high burden of infectious disease and overcrowding [11, 12]. Sporadic 
cases of PSGN occur in the Northern Territory of Australia each year with outbreaks 
every 5-7 years [13]. PSGN in New Zealand occurs mostly in children of Pacific Island and 
Maori heritage (>85% of cases) [14]. Sporadic cases of PSGN also continue to be reported 
from all over the world.  
The rates are higher in children than in adults, and PANDAS is described solely in the 
paediatric age group. PSGN primarily affects children, aged 2-12 years, with clinically 
detectable cases estimated to be 10% of children with pharyngitis and up to 25% of children 
with impetigo during epidemics [15, 16]. Children account for 50-90% of epidemic cases, 
with 5-10% occurring in people > 40 years and 10% in those below 2 years of age [5]. PSGN 
is uncommon below 3 years of age and rarely seen below 2 years [17]. This low incidence of 
PSGN is likely to be due to the decreased immunogenicity of children below 2 years of age, 
for although GAS pharyngitis is uncommon in children of this age, GAS skin infections are 
common. Decreased immunogenicity likely results in less robust immune complex 
formation thus leading to less PSGN [18]. 
Males have more symptomatic disease, but this difference is no longer present when 
symptomatic and asymptomatic cases are considered together [19]. Spontaneous recovery 
occurs in almost all patients, including those who develop renal insufficiency during the 
acute phase [16], with 1% of all paediatric patients developing renal insufficiency.  
There are no large scale published studies of bacterial infections associated with GN other 
than streptococcal infection. These are limited to small cases series and individual cases 
reports. The most common of these are related to staphylococcal infections, both methicillin 
sensitive [20] and methicillin resistant [21, 22]. A case series of 10 cases, age range 21-65 
years, of MRSA-associated glomerulonephritis reported polyclonal increases of IgA and IgG 
and massive T cell activation and suggested the role of the enterotoxin as a bacterial super-
antigen initiating the immunological response leading to the glomerulonephritis [22]. The 
histopathologic findings on immunofluorescence in the patients with MRSA infection with 
nephritis resemble those seen in IgA nephropathy [22]. Nephritis associated with 
endocarditis and ventricular shunts is associated with staphylococcal infection [22]. A 
number of infections can cause nephritis as listed in table 1. Most have been reported as case 
reports, such as a report of nephritis following malaria due to falciparum vivax infection in a 
7 year old girl [23], and a report of nephritis following pneumococcal pneumonia in an adult 
male [24].  
Hepatitis-B-associated glomerulonephritis (HBGN) is a distinct entity occurring frequently 
in hepatitis-B-prevalent areas of the world. The disease affects both adults and children who 
are chronic hepatitis-B-virus (HBV) carriers with or without a history of overt liver disease. 
The diagnosis is established by serologic evidence of HBV antigens/antibodies, presence of 
an immune complex glomerulonephritis, immunohistochemical localization of 1 or more 
HBV antigens and pertinent clinical history [25]. With the high incidence of hepatitis B in 
Asia, this entity assumes a greater public health importance. A study from China reported 
205 cases from a single hospital from September 1995 to November 2008 [26]. In this series, 
the peak incidence of HBV-GN was between 20 -40 years of age, with a 3:1 predominance of 
males. The most common clinic manifestation was nephrotic syndrome and the most 
common pathology was membranous nephropathy. Decreased renal function was present in 
10% of cases. The degree of albuminuria correlated with the viral load [26]. 
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Renal disease is not uncommon in those infected with HIV. The most common 
manifestation of HIV in the kidney is HIV-associated nephropathy (HIVAN). 
Immunotactoid glomerulonephritis is a rare disorder found in 0.06% of renal biopsies 
characterized by organized tubular immune complex deposits. This is seen more commonly 
Caucasians and tends to occur in an older age group. There are 6 reported cases of HIV 
associated immunotactoid glomerulonephritis [27]. 
3. Pathogenesis 
The kidney has a limited number of ways of responding to injury. Similar pathological signs 
may be the end result of different processes, produced by different initiating mechanisms 
and different molecular pathways may perpetuate the injury process. The initiation and 
development of the inflammatory response of the kidney to infection are still poorly 
understood.  
The pathognomonic feature of PSGN is the deposition of immune complexes in the 
glomerular basement membrane. A proposed sequence of events is that a nephritogenic 
antigen(s) leads to the activation of the complement pathway and/or activates plasmin or 
production of the circulating immune-complexes. These then lead to increased permeability 
of the glomerular basement membrane, which allows deposition of the immune complexes, 
and leakage of the protein and red blood cells. The nephritogenic antigen is responsible for 
the C3 deposition, the recruitment of immune cells, tissue destruction and IgG deposition 
which further aggravates tissue injury. Complement activation leads to the release of 
cytokines, such as C5a, which attracts phagocytes, and proliferation of intrinsic cells and 
formation of a membrane attack complex which also aggravate the process. The definitive 
nephritogenic antigen has not yet been defined, although a large number of streptococcal 
factors (M proteins) have been proposed as the triggering factor. M proteins are present on 
the pili of the organism and more than 100 have been identified so far. Nephritogenic M 
proteins are types 1, 2, 4, 3, 25, 49, and 12 following skin infections and types 47, 49, 55, 2, 60, 
and 57 following throat infections [28]. Infections with nephritogenic streptococci have 
considerable variability in their ability to cause nephritis. The reason for this variability is 
not known. 
Pathology shows typical glomerular changes which include proliferation of mesangial, 
endothelial and epithelial cells, inflammatory exudate and deposition of C3 early in the 
disease process followed by deposition of IgG. This immune deposition has been classified 
into 3 patterns [29]. The “starry sky” pattern represents an irregular and finely granular 
deposit of C3 and IgG along the glomerular capillary walls and in the mesangium. This 
occurs early in the course of the disease and is also seen in subclinical cases [28, 29]. The 
“mesangial pattern” has mainly C3 and some IgG in the mesangium. The “garland pattern” 
shows dense deposits along the capillary walls, is commonly associated with severe 
proteinuria and a poor prognosis [28, 29].  
The immunological response of the kidney to an insult results in glomerulonephritis. The 
causal factors that underlie acute GN can be broadly divided into infectious and 
noninfectious groups. The most common infectious cause of acute GN is infection by 
Streptococcus species (ie, group A, beta-hemolytic). Nonstreptococcal postinfectious GN may 
also result from infection by other bacteria, viruses, parasites, or fungi. Bacteria besides 
group A streptococci that can cause acute GN include diplococci, other streptococci, 
staphylococci, and mycobacteria. Salmonella typhosa, Brucella suis, Treponema pallidum, 
Corynebacterium bovis, and actinobacilli have also been identified.  
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In the absence of evidence of a recent group A beta-hemolytic streptococcal infection, 
infections with Cytomegalovirus (CMV), coxsackievirus, Epstein-Barr virus (EBV), hepatitis 
B virus (HBV) [30], rubella, rickettsiae (as in scrub typhus), and mumps virus may be 
accepted as causal organisms. Similarly, attributing glomerulonephritis to a parasitic or 
fungal etiology requires the exclusion of a streptococcal infection. Possible organisms are 
Coccidioides immiti, Plasmodium malariae, Plasmodium falciparum, Schistosoma mansoni, 
Toxoplasma gondii, filariasis, trichinosis, and trypanosomes. While hepatitis B infection has 
been well documented as a cause of renal involvement and glomerulonephritis [25, 26], 
acute GN is as a rare complication of hepatitis A [31]. 
Noninfectious causes of acute GN may be divided into primary renal diseases, systemic 
diseases, and miscellaneous conditions or agents. The primary renal diseases are 
membranoproliferative glomerulonephritis (MPGN), IgA nephropathy and mesangial 
proliferative glomerulonephritis. Multisystem systemic diseases that can cause acute GN are 
vasculitis such as Wegener granulomatosis, polyarteritis nodosa and hypersensitivity 
vasculitis, collagen-vascular diseases like systemic lupus erythematosus (SLE) which causes 
glomerulonephritis through renal deposition of immune complexes, Henoch-Schönlein 
purpura and Goodpasture syndrome. Miscellaneous noninfectious causes are Guillain-Barré 
syndrome, Diphtheria-pertussis-tetanus (DPT) vaccine and serum sickness. These are 
summarised in table 1.  
It is important to identify the exact aetiology of the glomerulonephritis as the prognosis 
differs widely depending on the underlying cause. There are a number of clinical and 
laboratory features that may help to differentiate between or even point to a particular cause 
of glomerulonephritis. The latent period between infection and nephritis is helpful in 
differentiating PSGN from IgA nephropathy. In contrast to the latent period of 2-3 weeks 
seen in PSGN, the nephritis of IGA nephropathy may occur either at the same time or just 1-
2 days after an upper respiratory infection. Similarly, patients with nephritis of chronic 
infection have an active infection at the time nephritis becomes evident. Despite the chronic 
nature of the underlying infection, the associated nephritis can present acutely. Circulating 
immune complexes play an important role in the pathogenesis of acute GN in these 
diseases.  
The failure of the C3 levels to return to normal should prompt consideration of the 
possibility of MPGN or SLE as the underlying cause. MPGN is a chronic disease which can 
manifest with an acute nephritic picture. Gross haematuria is unusual in lupus nephritis. 
Other associated systemic findings may identify the underlying systemic disease, for 
example, vasculitic lesions of the lower extremities point to an underlying vasculitis as the 
cause of glomerulonephritis.  
4. Clinical presentation 
The typical presentation is the abrupt onset of acute nephritis occurring 1-3 weeks after a 
streptococcal throat infection and 3-6 weeks after skin infection [28]. The nephritis is 
characterised by the triad of oedema, gross haematuria, and hypertension. The classical 
presenting feature is the presence of “coca-cola” coloured urine which is characteristic of 
homogenous gross haematuria [32]. Other common features are facial puffiness and 
hypertension secondary to fluid overload and urinary abnormalities such as albuminuria 
and the presence of red cell casts. General features like malaise, weakness, and anorexia may 
occur in about half the patients and a minority complain of nausea and vomiting. Within a 
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week or so from onset of symptoms, most patients with PSGN begin to experience 
spontaneous resolution of fluid retention and hypertension and the urine abnormalities 
begin to subside. The low C3 levels begin to rise and normalise by 8 weeks. Normal urine 
findings are found by 12 weeks.  
Microscopic haematuria is universally present. Of the triad of features, oedema is seen in 
85% of cases and is often the presenting symptom, gross haematuria in 40% of cases (range 
30-50%) and hypertension in 50-95% of hospitalised cases. Approximately 95% of clinical 
cases have at least 2 manifestations, and 40% have the full-blown acute nephritic syndrome. 
The puffiness of the face or eyelids is sudden, usually prominent upon awakening and tends 
to subside at the end of the day if the patient is active. The oedema is a result of a defect in 
renal excretion of salt and water leading to fluid overload. The severity of edema does not 
correlate well with the degree of renal impairment. 
In most cases, urinary abnormalities clear by 12 weeks, although proteinuria may persist for 
6 months to 3 years and microscopic haematuria from 1 year to 4 years after the onset of 
nephritis [33]. In some cases, generalized edema and other features of circulatory 
congestion, such as dyspnea, may be present. 
Accompanying this clinical picture is laboratory evidence of streptococcal infection, 
typically increasing antistreptolysin-O titers (ASOT) or streptozyme titres following throat 
infections and anti-DNase B titers following skin infections. Complement levels are 
decreased; low C3 levels are found in almost all patients with acute PSGN and C4 levels 
may be slightly low. These low levels of C3 usually normalize within 8 weeks after the first 
sign of PSGN [34], although up to 12 weeks has been reported [33]. The typical 
accompanying histopathology is one of diffuse cellular proliferation in the glomerulus, an 
exudate containing neutrophils and monocytes and variable degrees of complement and 
immunoglobulin deposition. In most cases, hypertension subsides, renal function returns to 
normal and all urinary abnormalities eventually disappear [33]. 
There is, however, a wide variation in the clinical presentation as well in the histopathology 
associated with PSGN. At the severe end of the spectrum is a rapidly rising azotemia with a 
rapidly progressive nephritic picture associated with severe cell proliferation, massive 
exudates and crescent formation in biopsy specimens. This is seen in <5% of PSGN cases 
[19]. The severity of renal failure tends to be directly related to the degree of proliferation 
and crescent formation, and about 50% of these patients recover renal function [35]. This 
type of presentation is more common in the elderly. The mild end of the spectrum, 
represented by subclinical or asymptomatic glomerulonephritis, is more common. Diligent 
examination of people with acute, trivial or self-limited infections caused by a range of 
organisms including various bacteria, parasites or viruses reveal subclinical infection in the 
form of microscopic hematuria, proteinuria and pyuria. Histopathology reveals mesangial 
proliferation with mesangial deposits of C3 and IgG deposits [19]. Asymptomatic household 
contacts of PSGN cases show sub-clinical disease 4-5 times more commonly than the acute 
classical presentation [6, 36]. An older study puts the ratio of asymptomatic cases as high as 
19:1 [7].  
5. Typical findings on investigations  
Urinalysis reveals haematuria in all patients and proteinuria (from trace to 2+ on dipstick 
testing) is usually present. Proteinuria may be in the nephrotic range and is usually 
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associated with more severe disease. Red blood cell casts are pathognomonic of acute 
glomerulonephritis. Occasionally other cellular casts and pyuria are present.  
Serological evidence of an antecedent streptococcal infection is present in the form of raised 
ASOT (> 200 IU/ml) and increased anti-DNAse B (which is a better serological marker of 
preceding streptococcal skin infection). Bacteriological evidence of streptococcal disease 
may be present in throat or skin swabs.  
Complement levels especially C3 are low at the onset of symptoms. C4 is usually within 
normal limits in post-streptococcal GN. Causes of nephritis with low complement besides 
PSGN are MPGN, SLE, cryoglobulinemia, Diabetes Mellitus and Hepatitis C Virus. These 
diseases should be screened for in case of either an atypical presentation or atypical clinical 
course of the glomerulonephritis.  
Renal function tests, blood urea, sodium, potassium and serum creatinine may be elevated 
in the acute phase and reflect the decrease in the glomerular filtration rate that occurs at this 
time. These elevations are usually transient. Failure of renal function tests to normalize 
within several weeks or months suggests that the patient may not have PSGN and indicates 
the need to seek an alternative diagnosis by further investigation. The full blood count may 
show anaemia which is usually dilutional and will return to normal once the fluid overload 
resolves.  
Renal ultrasound is not required to make a diagnosis of glomerulonephririts. Renal 
ultrasound images usually reveal normal-sized kidneys bilaterally. Renal imaging is often 
done to confirm that there are two kidneys and that they are structurally normal. It may be 
done as a prelude to a renal biopsy. PSGN is a clinical diagnosis and requires the detection 
of glomerulonephritis and evidence of preceding streptococcal infection. A renal biopsy is 
indicated in cases with an atypical presentation, an atypical course, persistence of clinical 
features, or a persisting low level of complement (C3) or abnormal renal function tests. 
Features that suggest a diagnosis other than PSGN in the early stages may also indicate a 
need for a biopsy. These include the absence of the latent period between streptococcal 
infection and acute glomerulonephritis, anuria, rapidly deteriorating renal function, normal 
serum complement levels, lack of rise in antistreptococcal antibodies, general symptoms of 
systemic disease and either persistent hypertension or lack of improvement in glomerular 
filtration rate for more than 2 weeks. In the recovery phase, persistent low C3 beyond 8 and 
definitely beyond 12 weeks from the onset of illness would indicate a need to look for 
alternate causes and for a renal biospsy.  
6. Treatment  
Treatment of PSGN remains largely supportive. Complete recovery occurs in over 90% of 
children, but only 60% of adults fully recover. The rest develop hypertension or renal 
impairment. 
Treatment is directed towards monitoring the signs and symptoms, in particular facial 
puffiness and hypertension, the main cause of which is fluid overload. Treatment when it is 
required, is mainly directed towards managing the fluid overload, which is responsive to 
diuresis and sodium restriction. Effective diuresis reduces cardiac congestion and controls 
hypertension and in most cases no further treatment is required. Strict input-output 
monitoring is recommended during the acute phase.  
As the hypertension is caused by fluid overload, loop diuretics are the first line treatment 
and may be adequate for control of hypertension. Furosemide in a dose of 40 mg either 
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orally or intravenously is given 12 hourly. Usually treatment is required for less than 48 
hours. Sometimes other anti-hypertensive agents may be needed, especially when the blood 
pressure is very high and it is unsafe to wait for the effect of diuretic therapy. Nifedipine is 
then given every 4-6 hours in doses of 5-10 mg. Rarely parenteral hydralazine may be 
required. Captopril has shown to be effective [37, 38] but should be used in caution in the 
presence of renal failure and hyperkalemia. Occasionally acute renal failure requires 
dialysis. Pulmonary oedema may be complication of severe fluid overload and needs urgent 
treatment. 
It is important to check serum complement levels 6-8 weeks after initial testing to make sure 
they have returned to normal. Blood pressure should be monitored every month for 6 
months and then 6 monthly. Renal function tests and serum creatinine levels repeated every 
3 months after the acute phase for 1 year and then yearly after that. Urine should be checked 
for hematuria and proteinuria every 3-6 months. 
Aggressive therapy using pulse methyprednisolone has been used in adults with poor 
prognostic factors such as nephritic range proteinuria, cellular crescents on biopsy and renal 
insufficiency [39]. Plasmapharesis and pulse methyprednisolone was successfully used in a 
6 year old girl with garland pattern PSGN [40]. Whether this would benefit all patients with 
poor prognosis has not been studied.  
Penicillin treatment is given to treat any persisting streptococcal infection [41]. Methicillin 
resistant staphylococcus should be treated with appropriate antibiotics. Specific infections 
require treatment with specific antibiotics or antiviral agents. Treatment of the underlying 
infection may resolve the glomerulonephritis as well. A review of six trials (a total of 159 
patients) of which five were specified as hepatitis B virus-associated membranous 
glomerulonephritis (HBV-MN) showed that antiviral therapy for hepatitis B infections 
including IFN and lamivudine is effective in leading to remission of proteinuria, HBeAg 
clearance, and HBV-DNA reduction in both children and adults [42]. 
7. Preventing spread  
A case of PSGN has 2 or more of the following clinical manifestations: oedema, macroscopic 
hematuria or dipstick hematuria of ≥ 2, or diastolic blood pressure of >80mmHg if ≤ 13 
years of age and >90 mmHg if >13 years of age, in the presence of a reduced complement 
level (C3) and evidence of streptococcal infection by either elevated ASO or anti-DNAse B 
titres or positive cultures of GAS from skin, if sores are present, or from the throat in the 
absence of skin sores.  
There is evidence that outbreaks can be halted by treating all children with any evidence of 
skin sores with intra-muscular (IM) benzathine penicillin to stop the transmission of the 
bacteria in the community [43]. In experimental PSGN, the nephritic process is prevented if 
penicillin is given within 3 days of the streptococcal infection [41]. Prevention of epidemics 
requires the control of spread of skin sores and infected scabies [44]. Following the 
identification of a case(s), family and household members are screened for the presence of 
skin sores and scabies and tested for urinary abnormalities. Those with skin manifestations 
are treated with penicillin. Those with urinary abnormalities undergo complete 
investigation for PSGN including urea, electrolytes, C3, ASO, anti-DNAse B and cultures for 
streptococcal infection.  
Prevention of epidemics of PSGN requires a community level control of skin sores and 
infected scabies. Promotion of regular washing, especially of children, will prevent spread. 
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Improvement in housing, especially reduction in overcrowding, will hinder spread of 
infectious disease. The significant decline in PSGN in Singapore children is attributed to an 
improvement in the socioeconomic status, the health care system and urbanization of the 
country [9]. 
Although research into the development of a vaccine is advanced and 3 GAS vaccines have 
been approved for phase 1 human trials [45], it is unlikely to be available in the near future. 
8. Prognosis  
In keeping with the clinico-pathological picture, the prognosis of PSGN is also extremely 
variable, and largely influenced by clinical presentation and histopathology. An episode of 
PSGN may result in complete recovery, progression of symptoms or progression to renal 
failure. Persistence of symptoms may represent either a slow recovery, limited injury 
without further progression or progression to renal failure.  
The immediate prognosis is generally good. In general, children are believed to have an 
excellent prognosis with the majority showing complete recovery [5]. Fewer than 1% of 
children have elevated serum creatinine values after 10-15 years of follow-up. Adults have a 
poorer prognosis overall. Early mortality can be as high as 25% in the elderly who have 
congestive cardiac failure or azotemia in the early phase. In adults approximately 25% will 
progress to chronic renal failure. These are usually those with massive proteinuria which 
suggests a worse prognosis and often signifies the garland pattern of immune deposits on 
pathology.  
It is difficult to predict the prognosis in an individual case particularly early in the disease. 
While a typical presentation and clinical course indicates a good prognosis and an atypical 
presentation, severe persistent hypertension and abnormal renal function tests, massive 
proteinuria and older age group suggest a poor prognosis, there is a lack of a clinical or 
biochemical marker that might differentiate those with a good prognosis from those with a 
poorer outcome. Neutrophil gelatinase-associated lipocalin (NGAL), is emerging as a 
promising biomarker of acute kidney injury [46, 47], but has not yet been evaluated in PSGN.  
However, some studies have reported persistent urinary abnormalities [8, 11, 19, 48, 49] and 
subtle abnormalities in renal function, as defined by reduction in renal functional reserve, in 
patients who had recovered from PSGN without apparent sequelae [50]  
Epidemic cases have a better prognosis than sporadic cases [14, 51, 52], but not always. An 
outbreak of PSGN in Brazil following an epidemic of Streptococcus equi zooepidemicus 
resulted in a high prevalence of renal abnormalities at a mean follow-up of 5.4 years [53, 54]. 
These were, however, mainly adult patients. A study of Iranian children has shown that 
even mild PSGN may result in impaired renal function and that a rising diastolic blood 
pressure may be an early sign of worsening renal function [55].  
Elderly people have poorer outcomes as do those with co-morbidities, including diabetes, 
cardiovascular and liver diseases [5, 28]. In an Aboriginal population with high rates of 
ESRD, follow-up of children 6-18 years (mean 14.6 years) after epidemic PSGN showed that 
risk of overt proteinuria was 6 times ( 95% CI 2.2-16.9) greater than in healthy controls after 
adjustment of age, sex and birth weight [11, 56]. The Australian Aboriginal population is at 
considerably higher risk than the general Australian population of developing chronic 
diseases such as diabetes mellitus, cardiovascular and renal diseases. There is also a greater 
burden of infectious disease and adverse early life factors such as low birth and infant 
weights. It is proposed that in this high risk population with multiple adverse renal 
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influences, childhood PSGN might be a more important risk factor for ESRD than it would 
be in lower risk populations [11, 44, 57].  
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